Global Ovarian Cancer Drugs Market Report – By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy, Radiation Therapy, and Other Therapies), By Distribution Channel ( Drug Stores and Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The Global Ovarian Cancer Drugs Market size is expected to be worth around USD 9,857 Mn by 2032 from USD 2,678 Mn in 2022, growing at a CAGR of 14.3% during the forecast period from 2022 to 2032.

The very frequent cause of death for females with gynecological cancers is ovarian cancer. In addition, it is the 7th most frequent cause of female death worldwide. Most cases are discovered after the condition has already progressed to the point where it is fatal. This anxiety is made worse by the present screening tests’ low predictive value.

Cancer mortality and morbidity have not been significantly reduced by frequent early identification methods, such as transvaginal ultrasound, a comprehensive gynecological examination, and laboratory markers like the cancer antigen-125 assay. The most common cancer treatments are surgery and chemotherapy, with platinum as the chemotherapy agent.

However, over the past 10 years, poly (ADP-ribose) polymerase (PARP) inhibitors and anti-angiogenic bevacizumab have become increasingly popular in treating this cancer. After the early treatment, there has also been a high recurrence rate. Most of these relapsed patients are known to have a greater rate of treatment failure and a lower chance of recovery. Therefore, it is more important than ever to develop novel treatment strategies based on an in-detail comprehension of the malignancy’s molecular characteristics.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• High Incidence Rates of Ovarian Cancer: Ovarian cancer drug sales are driven by its rising incidence rates and its status as one of the primary cancer-related killers among women.
• Limitated Early Detection: Ovarian cancer often presents with vague symptoms and lacks effective early detection methods; hence highlighting the need for advanced therapies and advanced detection measures.
• Advancements in Therapies: Ongoing research and development have resulted in targeted and personalized treatments, improving the outlook for those living with ovarian cancer.
• Chemotherapy Dominance: While chemotherapy was once the mainstay treatment option for ovarian cancer, more targeted therapies and immunotherapies are becoming popular options in recent years.
• PARP Inhibitors: With their introduction, PARP (Poly ADP-Ribose Polymerase) inhibitors have represented an enormous advancement in treating ovarian cancer – particularly among those carrying BRCA mutations.

Therapy Analysis

The Targeted Therapy Will Continue to Dominate the Global Ovarian Cancer Market Over the Forecast Period.

The market is divided into targeted therapy, chemotherapy, and other categories. It is anticipated that the targeted therapy segment will continue to dominate the global market in the forecast period. This is because specific targeted therapies can mark cancer cells, making it easier for the immune system to eliminate and identify them.

Also, some targeted cancer therapies have the potential to enhance the immune system’s ability to combat cancer, thereby further accelerating market expansion effectively. In addition, the rise in the incidence of cancers like gynecological, ovarian, and breast cancer is also propelling the development of targeted therapies for cancer treatment. Research companies invest a lot of money in creating biologically targeted drugs.

Distribution Analysis

Hospital Pharmacy Held The largest Share of the Ovarian Cancer Drugs Market

Hospital pharmacies, retail pharmacies, drug stores, and online pharmacies make up the market. Due to an increase in ovarian cancer prevalence and healthcare spending, the hospital pharmacy held the largest share of the ovarian cancer drugs market. In addition, the primary responsibility for monitoring the availability of all hospital-used medications lies with the hospital pharmacy.

Patients’ trust in hospitals due to their easy access and high-quality services to medicines is primarily responsible for expanding hospital pharmacies. As ovarian cancer treatment is mainly done in hospitals, there has been an increase in hospital admissions, which has helped this market grow. In addition, the market’s expansion is further fueled by the rise of hospital pharmacies and an improvement in their structure in developing nations like India and China.

Key Market Segments

Based on Therapy

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Hormonal Therapy
• Radiation Therapy
• Other Therapies

Based on Distribution Channel

• Drug Stores & Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Drivers

Increased Sensitivity of Equipments is Responsible for Driving the Market over the Forecast Period.

One of the key drivers of this market’s expansion is the equipment’s increased sensitivity and result accuracy. The market is anticipated to expand significantly in the coming years due to the high specificity and improved technology of CT scans.

The ovarian drugs market is poised for growth and innovation in the pharmaceutical industry. This is due to a large pool of health-conscious customers. The market is expected to grow positively due to the positive impact of key players around the world approving various ovarian cancer medications.

Restraints

High cost of medicines

The high cost of gynecology medications hampers the market’s expansion. Most patients cannot afford these medications due to their high cost. The market’s expansion is hindered because most families from emerging economies hesitate to visit hospitals because they cannot pay for expensive medications and treatments.

Trends

CT Segment is Estimated to Show the Highest Growth Over the Forecast Period.

An imaging procedure known as computed tomography (CT) uses specialized X-ray equipment to produce detailed pictures, or scans, of specific body parts. Computerized axial tomography (CAT) and computerized tomography are two other names. This apparatus assists in determining whether the cancer is expanding into nearby structures and if larger tumors are present.

Additionally, indications of cancer spreading to the liver or other organs aids in identifying enlarged lymph nodes and indications that an ovarian tumor is affecting the kidneys or bladder. Due to the high importance of CT scans, there is an increasing demand for CT procedures to diagnose ovarian cancer, contributing to the segment’s expansion.

Regional Analysis

North America held the Largest Share of the Global Ovarian Cancer Drugs Market.

Due to the rising prevalence of ovarian cancer there, North America dominates the ovarian cancer drug market with 38% of the share. During the forecast period, the ovarian cancer drug market will also expand due to increased acceptance of novel therapeutics, new product launches, and a large target population.

Due to the excellent healthcare reforms and the rising incidence of ovarian cancer, it is anticipated that the ovarian cancer drug market in Asia-Pacific will undergo significant change. In addition, the region’s ovarian cancer drug market is expected to expand in the coming years due to a lack of control, a low-cost base, and cultural inhibitions.

The ovarian cancer drugs market is forecast to expand at the highest rate in Asia-Pacific. The existence of pharmaceutical companies in the region and the rising trading ability of populated nations like India and China are responsible for the market expansion in this region.

In addition, the market’s expansion is driven by an increase in the cost of personalized medicine and the use of advanced processing to enhance the manufacturing of ovarian cancer drugs. The region’s high population, rising disposable incomes, and unsatisfied medical needs contribute to the market’s expansion. In addition, Asia-Pacific is a successful market for drugs used to treat ovarian cancer because of the improvement of healthcare infrastructure and the rise of medical tourism.

In addition, the surge in advancements in drug discovery the market expansion is driven by an increase in the aging population of women, an increase in capital provided by private and government organizations, an increase in the amount of healthcare reforms, and an increase in funding.

In addition, the primary driving force behind the expansion of the Asia-Pacific market is the rising demand for cutting-edge healthcare services in developing economies like China and India. Due to the expanding infrastructure of industries, rising disposable incomes, and the well-established presence of domestic companies in the region, Asia-Pacific presents major players functioning in the drugs market with profitable opportunities.

As a result, the area is expected to register the speediest growth rate over the course of the forecast period. Additionally, the rising number of contract manufacturing companies in the region presents a fantastic opportunity for newcomers.

Key Regions

• North America
  • The US
  • Canada
  • Mexico

• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe

• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe

• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC

• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America

• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Siemens Medical Solutions Inc. got the Approval of the FDA for Siemens NAEOTOM Alpha.

The market’s expansion is also aided by regulatory authorities approval. For instance, Siemens Medical Solutions Inc. received FDA approval for Siemens NAEOTOM Alpha in September 2021.

This cutting-edge computed tomography device is made to turn information from X-ray photons that travel through a patient’s body and are received by a detector into a precise three-dimensional image. A few major companies in the market are Bristol Myers Squibb Company, Boehringer Ingelheim, Merck KGaA, Syndax Pharmaceuticals, Boehringer Ingelheim GmbH, Aetera Zenteris Inc., Johnson & Johnson Services, Amgen Inc. and other market players.

Below are some of the most prominent global ovarian cancer drugs market key players.

Market Key Players

• Genentech Inc.
• GlaxoSmithKline plc
• Roche
• Johnson & Johnson
• ImmunoGen
• Janssen Pharmaceuticals, Inc.
• Eli Lilly and Company
• Pfizer
• Other Key Players.

Recent Developments

May 2022: After listing Apealea on Gelbe Liste, a German drug distribution website, HLB reported that Elevar Therapeutics, its subsidiary, began marketing the ovarian cancer treatment in Germany.

May 2022: The Food and Drug Administration of the United States granted ImmunoGen approval. Mirvetuximab soravtansine monotherapy in patients with folate receptor alpha high platinum-resistant ovarian cancer who have previously been treated with 1-3 prior systemic treatments was submitted in the Biologics License Application by the organization.

Report Scope